Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | General Counsel | April 29, 2026 | April 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date April 29, 2026 · Filed April 30, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,000 |
Reported balance
After 2026-04-29 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-04-29 · Purchase · Acquired 25,000 · Balance 196,000 F1: 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed Apr 29, 2026 21:11 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantCommon Stock | 25,000 | $1.89 | $47,250.00 |
DisclosureSEC source: 0001171843-26-002840 · ownership.xml · nonDerivative · entry 1 Anderman Jonathan · CIK 0002032625 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 F1 · balance_after: 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 16:00 UTC Amendment | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 25,000 | $1.89 | $47,250.00 |
DisclosureSEC source: 0001171843-26-002893 · ownership.xml · nonDerivative · entry 1 Anderman Jonathan · CIK 0002032625 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 F1 · balance_after: 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 720,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001171843-26-000051 · ownership.xml · derivative · entry 2 Anderman Jonathan · CIK 0002032625 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,000 Underlying: Common Stock · 720,000 shares Expires 2036-01-02 F3 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantCommon Stock | 150,000 | $5.17 | $775,500.00 |
DisclosureSEC source: 0001171843-26-000051 · ownership.xml · nonDerivative · entry 1 Anderman Jonathan · CIK 0002032625 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,000 F1 · shares: Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027. F2 · balance_after: 150,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 13:30 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | PurchaseCommon Stock | 20,000 | $1.54 | $30,800.00 |
DisclosureSEC source: 0001171843-25-002086 · ownership.xml · nonDerivative · entry 1 Anderman Jonathan · CIK 0002032625 · Gen Counsel & Corporate Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 22:09 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001171843-25-000825 · ownership.xml · derivative · entry 1 Anderman Jonathan · CIK 0002032625 · Sr VP, Gen Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2035-02-11 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting March 11, 2025. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 12:49 UTC | Compass Therapeutics, Inc. CMPX · Entity 5614 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001171843-24-004782 · ownership.xml · derivative · entry 1 Anderman Jonathan · CIK 0002032625 · Sr VP, Gen Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: CommonStock · 300,000 shares Expires 2034-08-13 F1 · derivative.exercise_date: The options vest over 48 substantially equal monthly installments starting September 13, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.